Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Dr. Jacob Soumerai provides a comprehensive 5-year follow-up on the multicenter Phase II trial of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) in treatment-naïve chronic lymphocytic leukemia, highlighting sustained undetectable minimal residual disease rates, retreatment outcomes, and the prognostic significance of MRD kinetics (ΔMRD400).

Laurent Greiller, MD

Latest:

The Evolving Treatment Landscape of Small Cell Lung Cancer

Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.

Soki Kashima, MD, PhD

Latest:

Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC

Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.

Carlo Contreras, MD

Latest:

Dr. Contreras on the Use of Surgical Resection in Desmoplastic Melanoma

Carlo Contreras, MD, discusses how continued investigations in desmoplastic melanoma could better inform the use of surgical resection in select patients.

Emily Arner, PhD

Latest:

Dr Arner on the Role of SETD2 Loss in Tumor Growth and Metastasis in ccRCC

Emily Arner, PhD, discusses research on the role of SETD2 loss in metastatic clear cell renal cell carcinoma ccRCC.

Joseph Gligorov, MD, PhD

Latest:

Novel Treatment Approaches Under Investigation for HER2+ mBC

Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.

Paolo Strati, MD

Latest:

Dr. Strati on the Investigation of Immunotherapy Combinations in Lymphoma

Paolo Strati, MD, discusses several ongoing investigations aiming to improve upon current immunotherapy combinations, highlighting the introduction of novel regimens into the treatment landscape of follicular lymphoma.

Anna Weiss, MD

Latest:

Dr Weiss on the Role of Breast Imaging in Breast Cancer Treatment Decision-Making

Anna Weiss, MD, discusses the significance of various imaging modalities in patients with breast cancer.

Alberto Montero, MD, MBA, CPHQ

Latest:

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Adnan F. Danish, MD

Latest:

Dr Danish on Post-CAR T-Cell Bridging Radiation Therapy Eligibility in High-Risk NHL

Adnan F. Danish, MD, discusses findings from a study evaluating the prevalence of patients with high-risk non-Hodgkin lymphoma who were eligible for bridging radiation therapy prior to receiving CAR T-cell therapy, as well as the outcomes of these patients following CAR T-cell therapy.

Marielle E. Yohe, MD, PhD

Latest:

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

Richardo D. Parrondo, MD

Latest:

Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

Key opinion leaders examine recent evidence on acquired BTK inhibitor resistance in chronic lymphocytic leukemia and analyze its implications for treatment sequencing decisions in clinical practice.

Olivier Harismendy, PhD

Latest:

Dr. Harismendy on the Challenges Faced With Molecular Testing in DCIS

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.